Journal: bioRxiv
Article Title: Modular platform for therapeutic drug delivery using trifunctional bio-orthogonal macromolecular conjugates
doi: 10.1101/2025.07.24.666613
Figure Lengend Snippet: (A) Schematic of the plasmid cleavage assay of BMC nuclease activity in vitro and upon electroporation in cells. ( B and C) In vitro cleavage efficiency of Cas9 BMCs containing V1, V2, or V3 Cas9 variants as cargo, Tf or Ab as carrier, and TAT as CPP. The cleavage efficiency was assessed using gel electrophoresis analysis of linearized DNA cleavage as quantified by image densitometry, normalized to a DNA loading control. Unconjugated native Cas9 variants and 3xNLS-SpCas9 parent molecule were used as baseline control for comparison. ( D lll I) Cellular BMC activity assessed upon electroporation in Kasumi-1 TLR cells and measured by FACS of mCherry-expressing cells. Cas9 BMCs containing V1 (D and E), V2 (F and G), or V3 (H and I) Cas9 variants as cargo, Ab as carrier, and TAT, TAT-EBV, TAT-Ebola, and A5K as CPP were tested. Unconjugated native Cas9 variants were used as baseline control for comparison. 3xNLS: 3xNLS-SpCas9; V1/V2/V3_Unconj: unconjugated native Cas9 variants. Data show 3 replicates.
Article Snippet: Linearized DNA substrate was first prepared by digesting 30 μg of plasmid DNA (final concentration 437 ng/μl) with 300 units of BsaHI restriction enzyme (New England Biolabs) in CutSmart Buffer (New England Biolabs) at 37 °C for 1 hr.
Techniques: Plasmid Preparation, Cleavage Assay, Activity Assay, In Vitro, Electroporation, Nucleic Acid Electrophoresis, Control, Comparison, Expressing